JP2008539182A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008539182A5 JP2008539182A5 JP2008508138A JP2008508138A JP2008539182A5 JP 2008539182 A5 JP2008539182 A5 JP 2008539182A5 JP 2008508138 A JP2008508138 A JP 2008508138A JP 2008508138 A JP2008508138 A JP 2008508138A JP 2008539182 A5 JP2008539182 A5 JP 2008539182A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- protein
- immunogenic fragment
- vaccine according
- excluded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccines Drugs 0.000 claims 44
- 108090000623 proteins and genes Proteins 0.000 claims 22
- 102000004169 proteins and genes Human genes 0.000 claims 22
- 230000002163 immunogen Effects 0.000 claims 20
- 241000341655 Human papillomavirus type 16 Species 0.000 claims 8
- 239000002671 adjuvant Substances 0.000 claims 7
- 230000000240 adjuvant Effects 0.000 claims 7
- 201000009910 diseases by infectious agent Diseases 0.000 claims 7
- 230000002246 oncogenic Effects 0.000 claims 6
- 231100000590 oncogenic Toxicity 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 102000005857 Human papillomavirus type 18 L1 protein Human genes 0.000 claims 3
- 101000162572 Major capsid protein L1 Proteins 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical group [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 2
- 230000002380 cytological Effects 0.000 claims 2
- 101710004056 CWINV1 Proteins 0.000 claims 1
- 101710004059 CWINV3 Proteins 0.000 claims 1
- 108060008088 TBCC Proteins 0.000 claims 1
- 101710015135 TPS27 Proteins 0.000 claims 1
- 230000003902 lesions Effects 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000002085 persistent Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/114,301 US20050287161A1 (en) | 2002-12-20 | 2005-04-26 | Vaccine |
| PCT/EP2005/006461 WO2005123125A1 (en) | 2004-06-16 | 2005-06-14 | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 |
| US11/367,601 US7858098B2 (en) | 2002-12-20 | 2005-12-16 | Vaccine |
| PCT/EP2006/003809 WO2006114273A2 (en) | 2005-04-26 | 2006-04-24 | Vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008539182A JP2008539182A (ja) | 2008-11-13 |
| JP2008539182A5 true JP2008539182A5 (ru) | 2009-04-23 |
Family
ID=37199195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008508138A Pending JP2008539182A (ja) | 2005-04-26 | 2006-04-24 | ワクチン |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1879614A2 (ru) |
| JP (1) | JP2008539182A (ru) |
| KR (1) | KR20080005583A (ru) |
| AR (1) | AR053715A1 (ru) |
| AU (1) | AU2006239471A1 (ru) |
| CA (1) | CA2606206A1 (ru) |
| EA (1) | EA013325B1 (ru) |
| MX (1) | MX2007013475A (ru) |
| NO (1) | NO20075185L (ru) |
| SG (1) | SG159529A1 (ru) |
| UY (1) | UY29499A1 (ru) |
| WO (1) | WO2006114273A2 (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2444103T3 (pl) * | 2009-06-19 | 2018-05-30 | Eyegene Inc. | Szczepionka przeciwko rakowi szyjki macicy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| US6908613B2 (en) * | 2000-06-21 | 2005-06-21 | Medimmune, Inc. | Chimeric human papillomavirus (HPV) L1 molecules and uses therefor |
| GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| NZ540811A (en) * | 2002-12-20 | 2007-03-30 | Glaxosmithkline Biolog S | Use of HPV 16 and HPV 18 VLPs in the prevention of infection or disease caused by one or more of the group of oncogenic HPV types excluding types 16 and 18 |
| JP2008502633A (ja) * | 2004-06-16 | 2008-01-31 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン |
-
2006
- 2006-04-24 MX MX2007013475A patent/MX2007013475A/es unknown
- 2006-04-24 CA CA002606206A patent/CA2606206A1/en not_active Abandoned
- 2006-04-24 EP EP06753410A patent/EP1879614A2/en not_active Ceased
- 2006-04-24 SG SG201000826-6A patent/SG159529A1/en unknown
- 2006-04-24 KR KR1020077027492A patent/KR20080005583A/ko not_active Application Discontinuation
- 2006-04-24 WO PCT/EP2006/003809 patent/WO2006114273A2/en active Application Filing
- 2006-04-24 AU AU2006239471A patent/AU2006239471A1/en not_active Abandoned
- 2006-04-24 JP JP2008508138A patent/JP2008539182A/ja active Pending
- 2006-04-24 EA EA200702077A patent/EA013325B1/ru unknown
- 2006-04-24 AR ARP060101618A patent/AR053715A1/es not_active Application Discontinuation
- 2006-04-26 UY UY29499A patent/UY29499A1/es not_active Application Discontinuation
-
2007
- 2007-10-11 NO NO20075185A patent/NO20075185L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1410805B1 (en) | Vaccine against HPV | |
| Gambhira et al. | Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2 | |
| Lowy et al. | Prophylactic human papillomavirus vaccines | |
| JP2006512413A5 (ru) | ||
| RU2014102200A (ru) | Вакцинные составы против вируса папилломы человека (hpv), содержащие алюминиевый адъювант, и способы их получения | |
| US20120093821A1 (en) | Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines | |
| CA2543928A1 (en) | Optimized expression of hpv 58 l1 in yeast | |
| WO2002090382A3 (fr) | Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications | |
| CA2539168A1 (en) | Optimized expression of hpv 45 l1 in yeast | |
| CA2519112A1 (en) | Optimized expression of hpv 31 l1 in yeast | |
| JP2007507207A5 (ru) | ||
| CA2510457A1 (en) | Hpv-16 and -18 l1 vlp vaccine | |
| Huber et al. | A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types | |
| JP2008539184A5 (ru) | ||
| CA2566620C (en) | Vaccine against hpv16 and hpv18 and at least another hpv type slected from hpv 31, 45 or 52 | |
| JP2008539182A5 (ru) | ||
| Mandic | Primary prevention of cervical cancer: prophylactic human papillomavirus vaccines | |
| Roden et al. | The impact of preventive HPV vaccination | |
| CN101116745B (zh) | 人乳头瘤病毒的病毒样颗粒疫苗 | |
| Webb et al. | Cervical cancer-causing human papillomaviruses have an alternative initiation site for the L1 protein | |
| US7858098B2 (en) | Vaccine | |
| JP2013540421A5 (ru) | ||
| JP2002532434A5 (ru) | ||
| Grce et al. | Burden and prevention of HPV related diseases: Situation in Croatia | |
| Hariharan et al. | Genotypes of the human papillomavirus: Relevance to Indian field trials of the vaccine |